US researcher awarded $3.6 million to study antibiotic resistance

Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has been awarded a $3.6 million grant from the National Institutes of Health (NIH) to expand current knowledge of antibiotic resistance, which will inform more precise antibiotic prescribing practices and help researchers develop drugs that are harder for bacteria to resist.  

Context 

Antibiotic resistance is responsible for at least 700,000 deaths a year, according to the World Health Organization. This number is expected to increase in the coming decades, making antibiotic resistance a growing and pressing threat to public health. 

Official comments 

“The emergence of antibiotic resistance is inevitable for any single drug, new or old. It’s only a question of time,” says Osterman. “But how much time is different for every drug and every microbe, so studying when and how resistance to antibiotics evolves gives us powerful information for improving antibiotic treatment.” 

How will the money be used? 

The research team is using a morbidostat, a device that allows bacteria to grow continuously over multiple generations while being dosed with antibiotics. They will use the device to track the precise progression of antibiotic resistance in several clinically relevant bacterial species. 

“It’s like an evolution machine, letting us watch the development of antibiotic resistance in real time and in an environment that models what happens to bacteria in a clinical setting more accurately than other approaches,” says Osterman. “This gives us a clearer and more comprehensive view of resistance than any we’ve had before.” 

In addition to expanding microbiology knowledge, the morbidostat approach has proven successful in preliminary studies. Working with Roche Pharma, Osterman’s team has completed morbidostat studies on several classes of antibiotic drugs. This approach is helping Roche identify promising candidates for antibiotics that are less prone to resistance. 

The project will also explore how this approach can be translated into better methods for treating infections with existing antibiotic drugs. 

Osterman said: “We are moving away from a trial-and-error approach to medicine, toward something much more calibrated. The tools we’re developing with this funding will allow doctors to select precisely optimised doses and combinations of antibiotics to maximise their benefit while minimising resistance.” 

Image credit: Sanford Burnham Prebys

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free